Our results demonstrated that long-term exposure of NSCLC cells to erlotinib results in the acquisition of tumor phenotypic features associated with EMT, a phenomenon that was more prominent with KRAS-mutated cell lines. This evidence concerns the gene KRAS and neoplasm.